person
as of 2026-07-01John M Kane, MD
John KaneJohn Kane, MD
at a glance
Roles: Principal Investigator, Author
KOL signal score 19
6 publications · 2 high-value
Cross-drug reach: 4 competitor drugs
Synthesized from structured facts only — each point cited above.
Profile
Affiliation
The Zucker Hillside Hospital
Roles
Principal Investigator, Author
KOL signal
19
Publications
6 (2 high-value)
Trial investigator
yes
Publishes on
4 drugs
Trials led
4
Improving Care and Reducing Cost Study
NCT02364544—Completed
Randomized, Double-blinded, Placebo-controlled, Evaluating the Treatment With LB-102 in Patients With Acute Schizophrenia
NCT06179108Phase 2Completed
Event Marker Ingested To Trigger Event Recorder 3.0 Psychiatry Study
NCT01804257—Completed
An Integrated Program for the Treatment of First Episode of Psychosis
NCT01321177—Completed
Publications & congress
6
Emraclidine, a novel positive allosteric modulator of cholinergic M4 receptors, for the treatment of schizophrenia: a two-part, randomised, double-blind, placebo-controlled, phase 1b trial.
Lancet (London, England) · 2022 · high-value
Efficacy and Safety of Lumateperone for Treatment of Schizophrenia: A Randomized Clinical Trial.
JAMA psychiatry · 2020 · high-value
Antipsychotic Efficacy and Safety of LB-102 in the Treatment of Adults With Acute Schizophrenia: A Randomized Clinical Trial.
JAMA psychiatry · 2026
Rethinking Amisulpride: Could N-Methylation Result in a New and Even Better Antipsychotic?
The Journal of clinical psychiatry · 2026
A New Treatment Paradigm: Targeting Trace Amine-Associated Receptor 1 (TAAR1) in Schizophrenia.
Journal of clinical psychopharmacology · 2022 Sep-Oct 01
Safety and tolerability of lumateperone for the treatment of schizophrenia: a pooled analysis of late-phase placebo- and active-controlled clinical trials.
International clinical psychopharmacology · 2021
Facts & assertions
0 sourced
No assertions recorded for this entity.
relationships
The graph out of here
publishes on
PRINCIPAL_INVESTIGATOR